These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31358581)

  • 1. A Parasite Biomarker Set for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic Trypanosoma cruzi Infection.
    Egui A; Thomas MC; Fernández-Villegas A; Pérez-Antón E; Gómez I; Carrilero B; Del Pozo Á; Ceballos M; Andrés-León E; López-Ruz MÁ; Gainza E; Oquiñena E; Segovia M; López MC
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential phenotypic and functional profile of epitope-specific cytotoxic CD8
    Egui A; López MC; Gómez I; Simón M; Segovia M; Thomas MC
    Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165629. PubMed ID: 31816438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological exhaustion and functional profile of CD8
    Pérez-Antón E; Egui A; Thomas MC; Simón M; Segovia M; López MC
    Acta Trop; 2020 Feb; 202():105242. PubMed ID: 31669531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients.
    Pérez-Antón E; Egui A; Thomas MC; Puerta CJ; González JM; Cuéllar A; Segovia M; López MC
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006480. PubMed ID: 29750791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A proportion of CD4+ T cells from patients with chronic Chagas disease undergo a dysfunctional process, which is partially reversed by benznidazole treatment.
    Pérez-Antón E; Egui A; Thomas MC; Carrilero B; Simón M; López-Ruz MÁ; Segovia M; López MC
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009059. PubMed ID: 33539379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
    Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
    J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin Enhances the Anti-Trypanosoma cruzi Activity of Benznidazole-Based Chemotherapy in Acute Experimental Chagas Disease.
    Novaes RD; Sartini MV; Rodrigues JP; Gonçalves RV; Santos EC; Souza RL; Caldas IS
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3355-64. PubMed ID: 27001816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
    Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
    Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.
    Torrico F; Gascon J; Ortiz L; Alonso-Vega C; Pinazo MJ; Schijman A; Almeida IC; Alves F; Strub-Wourgaft N; Ribeiro I;
    Lancet Infect Dis; 2018 Apr; 18(4):419-430. PubMed ID: 29352704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.
    Laucella SA; Mazliah DP; Bertocchi G; Alvarez MG; Cooley G; Viotti R; Albareda MC; Lococo B; Postan M; Armenti A; Tarleton RL
    Clin Infect Dis; 2009 Dec; 49(11):1675-84. PubMed ID: 19877967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers.
    Fernández-Villegas A; Pinazo MJ; Marañón C; Thomas MC; Posada E; Carrilero B; Segovia M; Gascon J; López MC
    BMC Infect Dis; 2011 Jul; 11():206. PubMed ID: 21801456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
    Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease.
    Jones K; Versteeg L; Damania A; Keegan B; Kendricks A; Pollet J; Cruz-Chan JV; Gusovsky F; Hotez PJ; Bottazzi ME
    Infect Immun; 2018 Apr; 86(4):. PubMed ID: 29311242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease.
    Vallejo A; Monge-Maillo B; Gutiérrez C; Norman FF; López-Vélez R; Pérez-Molina JA
    Acta Trop; 2016 Dec; 164():117-124. PubMed ID: 27619190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials.
    Sulleiro E; Muñoz-Calderon A; Schijman AG
    Acta Trop; 2019 Nov; 199():105120. PubMed ID: 31376368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains.
    Veloso VM; Carneiro CM; Toledo MJ; Lana M; Chiari E; Tafuri WL; Bahia MT
    Mem Inst Oswaldo Cruz; 2001 Oct; 96(7):1005-11. PubMed ID: 11685270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.
    de Andrade AL; Zicker F; de Oliveira RM; Almeida Silva S; Luquetti A; Travassos LR; Almeida IC; de Andrade SS; de Andrade JG; Martelli CM
    Lancet; 1996 Nov; 348(9039):1407-13. PubMed ID: 8937280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trypanosoma cruzi: Immunological predictors of benznidazole efficacy during experimental infection.
    Fernández MC; González Cappa SM; Solana ME
    Exp Parasitol; 2010 Feb; 124(2):172-80. PubMed ID: 19747482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the western Brazilian Amazon.
    Teston AP; Monteiro WM; Reis D; Bossolani GD; Gomes ML; de Araújo SM; Bahia MT; Barbosa MG; Toledo MJ
    Trop Med Int Health; 2013 Jan; 18(1):85-95. PubMed ID: 23130989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.